Your session is about to expire
← Back to Search
Hu8F4 for Blood Cancers
Study Summary
This trial looks at the side effects and best dose of the drug Hu8F4 for treating patients with blood cancers. The drug may help stop cancer cells from growing and spreading.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: Treatment (Hu8F4)
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What do researchers wish to determine through this experiment?
"This 4 week trial will primarily evaluate the safety of a given medication. The secondary objectives include Event-free Survival, Duration of Complete Remission and Overall Survival which can be estimated using Kaplan-Meier methods."
Is the research initiative currently recruiting participants?
"According to the clinicaltrials.gov registry, this medical trial is selecting participants at present. Initially posted on January 31st 2019, it was last modified by researchers on September 22nd 2022."
Has the FDA sanctioned Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4?
"Our team has assessed the safety of Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4 with a score of 1 due to the limited data available from it's current Phase 1 trial."
Share this study with friends
Copy Link
Messenger